Cantor Fitzgerald Weighs in on AQST FY2026 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings per share of ($0.81) for the year. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share.

A number of other research analysts also recently weighed in on AQST. Lake Street Capital decreased their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research note on Friday, March 7th. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Oppenheimer initiated coverage on Aquestive Therapeutics in a research note on Monday, June 2nd. They set an "outperform" rating and a $7.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Aquestive Therapeutics presently has an average rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Price Performance

AQST stock traded up $0.11 during mid-day trading on Wednesday, reaching $3.42. The company had a trading volume of 1,218,566 shares, compared to its average volume of 1,546,545. The stock has a 50 day simple moving average of $2.76 and a two-hundred day simple moving average of $3.08. The company has a market capitalization of $339.70 million, a price-to-earnings ratio of -7.60 and a beta of 1.94. Aquestive Therapeutics has a 52 week low of $2.12 and a 52 week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to analysts' expectations of $12.23 million.

Institutional Trading of Aquestive Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in Aquestive Therapeutics by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after purchasing an additional 3,821 shares during the period. MetLife Investment Management LLC boosted its stake in Aquestive Therapeutics by 11.4% in the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company's stock valued at $143,000 after purchasing an additional 4,125 shares during the period. Bank of Montreal Can boosted its stake in Aquestive Therapeutics by 10.1% in the 4th quarter. Bank of Montreal Can now owns 54,300 shares of the company's stock valued at $193,000 after purchasing an additional 4,999 shares during the period. Invesco Ltd. boosted its stake in Aquestive Therapeutics by 10.7% in the 1st quarter. Invesco Ltd. now owns 53,096 shares of the company's stock valued at $154,000 after purchasing an additional 5,152 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Aquestive Therapeutics by 3.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company's stock valued at $750,000 after purchasing an additional 7,129 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.